BioNTech SE Share Price

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

Delayed Nasdaq 20:46:15 22/04/2024 BST 5-day change 1st Jan Change
87.68 USD +1.01% Intraday chart for BioNTech SE -0.24% -16.92%

Financials

Sales 2024 * 2.79B 2.98B 241B Sales 2025 * 2.73B 2.91B 235B Capitalization 19.61B 20.89B 1,691B
Net income 2024 * -551M -587M -47.52B Net income 2025 * -503M -536M -43.38B EV / Sales 2024 * 2.02 x
Net cash position 2024 * 13.98B 14.89B 1,205B Net cash position 2025 * 13.65B 14.54B 1,177B EV / Sales 2025 * 2.19 x
P/E ratio 2024 *
-35.7 x
P/E ratio 2025 *
-43.6 x
Employees 6,133
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.00%
1 week-0.24%
Current month-4.95%
1 month-4.52%
3 months-12.15%
6 months-5.23%
Current year-16.92%
More quotes
1 week
85.40
Extreme 85.4
88.72
1 month
85.40
Extreme 85.4
93.84
Current year
85.21
Extreme 85.2129
114.70
1 year
85.21
Extreme 85.2129
125.83
3 years
85.21
Extreme 85.2129
464.00
5 years
12.53
Extreme 12.525
464.00
10 years
12.53
Extreme 12.525
464.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 01/06/08
Founder 57 01/06/08
Director of Finance/CFO 60 30/06/21
Members of the board TitleAgeSince
Director/Board Member 69 31/12/21
Director/Board Member 67 01/06/08
Chairman 53 01/06/08
More insiders
Date Price Change Volume
22/04/24 87.68 +1.01% 297 423
19/04/24 86.81 +0.74% 1,577,817
18/04/24 86.17 -0.27% 578,632
17/04/24 86.4 +0.07% 1,264,673
16/04/24 86.34 -1.76% 782,142

Delayed Quote Nasdaq, April 22, 2024 at 08:46 pm

More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
81.38 EUR
Average target price
106.4 EUR
Spread / Average Target
+30.76%
Consensus